Daniel Rizzo
Jefferies LLC, Research Division
Good morning. I’m Dan Rizzo from Jefferies Equity Research. Up next, we’ve got AptarGroup. With us today is CFO, Vanessa Kanu; our President, Alex Theodorakis, with the former division; and Mary Skafidas, who is VP of IR. There will be a 20-minute presentation followed by time for some Q&A. So without further ado, one of you guys want to kick it off?
Vanessa Kanu
Executive VP & CFO
Great. Let me just make sure I know how the clicker works. Fantastic. Thank you, Dan, and good afternoon, everyone. Thanks for taking the time to join us today and learn a little bit more about the Aptar story. So if you haven’t heard of us previously, then who is Aptar? We are a leader in drug consumer product, dosing, dispensing and protection technologies. And what that really means is that we are an expert in the end user.
We really do help to create the patient experience and the consumer experience. We’re also at our core technology company. We own the IP of everything we manufacture. We’re truly global. We operate in over 20 countries around the world across four different regions with Europe being our largest region. And for the year ended 2025, as you can see here, we generated about $3.8 billion in revenues across our three primary segments.
You can see here, Pharma was about 46% of revenue, about close to 70% of our adjusted EBITDA. Beauty was about 35% of revenue and about 18% of our adjusted EBITDA and Closures was about 19% of revenue and 13% of our
